Literature DB >> 17356955

Association of the presence of bone marrow micrometastases with the sentinel lymph node status in 410 early stage breast cancer patients: results of the Swiss Multicenter Study.

Igor Langer1, Ulrich Guller, Ossi R Koechli, Gilles Berclaz, Gad Singer, Gabriel Schaer, Mathias K Fehr, Thomas Hess, Daniel Oertli, Lucio Bronz, Beate Schnarwyler, Edward Wight, Urs Uehlinger, Eduard Infanger, Daniel Burger, Markus Zuber.   

Abstract

BACKGROUND: The sentinel lymph node (SLN) status has proven to accurately reflect the remaining axillary lymph nodes and represents the most important prognostic factor. It is unknown whether an association exists between the SLN status and the presence of bone marrow (BM) micrometastases. The objective of the present investigation was to evaluate whether or not such an association exists.
METHODS: In the present investigation 410 patients with early stage breast cancer (pT1 and pT2 <or=3 cm, cN0) were prospectively enrolled between 1/2000 and 12/2003. All patients underwent SLN biopsy and bone marrow aspiration. The histological examination of the SLN consisted of step sectioning, H&amp;E, and immunohistochemistry (Lu-5, CK 22) staining. Cancer cells in the BM were stained with monoclonal antibodies A45-B/B3 against cytokeratin and counted by an automated computerized digital microscope.
RESULTS: BM micrometastases were detected in 28.8% (118/410) of all patients. The SLN contained metastases in 32.4% (133/410). Overall 51.2% of the patients (210/410) were SLN negative/BM negative and 12.4% (51/410) SLN positive/BM positive. Of all patients, 16.4% (67/410) were SLN negative/BM positive and 20.0% (82/410) SLN positive/BM negative. There was a statistically significant association between the SLN and BM status, both in unadjusted (Fisher's exact test: P = .004) and multiple logistic regression analysis (P = .007).
CONCLUSIONS: In the present investigation a significant association was found between a positive SLN status and the presence of BM micrometastases. Nonetheless, the percentage of non-concordance (SLN negative/BM positive and SLN positive/BM negative) was considerable. The prognostic impact of BM micrometastases in our patient sample remains to be evaluated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356955     DOI: 10.1245/s10434-006-9193-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  4 in total

1.  Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype.

Authors:  James M Reuben; Bang-Ning Lee; Hui Gao; Evan N Cohen; Michel Mego; Antonio Giordano; Xuemei Wang; Ashutosh Lodhi; Savitri Krishnamurthy; Gabriel N Hortobagyi; Massimo Cristofanilli; Anthony Lucci; Wendy A Woodward
Journal:  Eur J Cancer       Date:  2011-02-19       Impact factor: 9.162

2.  Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples.

Authors:  T R Cawthorn; E Amir; R Broom; O Freedman; D Gianfelice; D Barth; D Wang; I Holen; S J Done; M Clemons
Journal:  Clin Exp Metastasis       Date:  2009-08-21       Impact factor: 5.150

3.  [Analysis of therapy-relevant receptors in bone marrow carcinosis : Comparison of pathological and clinical parameters].

Authors:  G Massenkeil; C Gropp; H Kreipe; K Hussein
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

4.  Prognostic value of hematogenous dissemination and biological profile of the tumor in early breast cancer patients: a prospective observational study.

Authors:  Montserrat Solá; Mireia Margelí; Eva Castellá; Juan F Julian; Miquel Rull; Josep M Gubern; Antonio Mariscal; Agustí Barnadas; Manuel Fraile
Journal:  BMC Cancer       Date:  2011-06-16       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.